Cantor Fitzgerald Reiterates "Neutral" Rating for Gossamer Bio (NASDAQ:GOSS)

Key Points

• Cantor Fitzgerald reaffirmed a "neutral" rating on Gossamer Bio (NASDAQ:GOSS); MarketBeat shows a consensus rating of "Hold" with a consensus price target of $5.43.
• Shares fell about 6.5%, trading near $0.42 with a market cap ~ $99M after Gossamer reported Q1 EPS of ($0.21) (missing estimates) and revenue of $13.8M, while remaining deeply unprofitable (negative net margin ~351%).
• Analyst opinions are mixed—four Buy, four Hold and two Sell—with several recent price-target cuts, and institutional ownership is high at about 81.23%.

Gossamer Bio (NASDAQ:GOSS - Get Free Report)'s stock had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday,Benzinga reports.

A number of other research firms have also weighed in on GOSS. Wall Street Zen lowered shares of Gossamer Bio from a "hold" rating to a "sell" rating in a research note on Friday, January 23rd. Wedbush reiterated a "neutral" rating and set a $1.00 price target (down from $6.00) on shares of Gossamer Bio in a report on Tuesday, February 24th. HC Wainwright dropped their price objective on shares of Gossamer Bio from $10.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, March 6th. Oppenheimer reduced their price objective on shares of Gossamer Bio from $12.00 to $3.00 and set an "outperform" rating on the stock in a report on Thursday, March 5th. Finally, Royal Bank Of Canada raised shares of Gossamer Bio to an "outperform" rating in a research report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Gossamer Bio presently has a consensus rating of "Hold" and a consensus price target of $5.43.

Gossamer Bio Trading Down 6.5%

Shares of NASDAQ GOSS opened at $0.42 on Monday. The stock has a market cap of $99.14 million, a P/E ratio of -0.56 and a beta of 2.09. The business's fifty day simple moving average is $1.65 and its 200-day simple moving average is $2.45. Gossamer Bio has a 12-month low of $0.33 and a 12-month high of $3.87.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The company had revenue of $13.80 million during the quarter, compared to analyst estimates of $7.53 million. Gossamer Bio had a negative net margin of 351.49% and a negative return on equity of 1,774.72%. On average, equities analysts forecast that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Legal & General Group Plc purchased a new stake in Gossamer Bio in the second quarter valued at $26,000. Ciovacco Capital Management LLC acquired a new stake in shares of Gossamer Bio during the third quarter worth about $27,000. Banco BTG Pactual S.A. purchased a new stake in shares of Gossamer Bio in the 2nd quarter valued at about $27,000. MMA Asset Management LLC purchased a new stake in shares of Gossamer Bio in the 4th quarter valued at about $31,000. Finally, Soltis Investment Advisors LLC acquired a new stake in shares of Gossamer Bio in the 4th quarter valued at about $31,000. 81.23% of the stock is owned by hedge funds and other institutional investors.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company's lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.